ArticleAmerican journal of translational research2017
Knockdown of REGγ inhibits proliferation by inducing apoptosis and cell cycle arrest in prostate cancer.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway.Experimental and therapeutic medicine · 2022Article
- Article
- Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.Cancer management and research · 2022Article
- circATP2A2 promotes osteosarcoma progression by upregulating MYH9.Open medicine (Warsaw, Poland) · 2021Article
- REG γ knockdown suppresses proliferation by inducing apoptosis and cell cycle arrest in osteosarcoma.PeerJ · 2020Article
- The oncogenic role of REG γ is exerted by activating the Wnt/β-catenin signaling pathway in osteosarcoma.American journal of translational research · 2020Article
- PA28γ, an Accomplice to Malignant Cancer.Frontiers in oncology · 2020Review
- Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1.Experimental biology and medicine (Maywood, N.J.) · 2019Article
- miR-500 promotes cell proliferation by directly targetting LRP1B in prostate cancer.Bioscience reports · 2019Article
- Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression.Journal of experimental & clinical cancer research : CR · 2019Article
- REGγ deficiency suppresses tumor progression via stabilizing CK1ε in renal cell carcinoma.Cell death & disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is the most common malignant tumor and the second leading cause of cancer related death among men in western countries. REGγ, a proteasome activator, is reported to play important roles in various human cancers. However, the expression patterns and potential roles of REGγ in prostate cancer have never been reported. In this study, we found for the first time that REGγ is overexpressed in prostate cancer tissues and cell lines at both protein and mRNA levels. In addition, we demonstrated that knockdown of REGγ significantly inhibited cell proliferation and induced apoptosis and cell cycle arrest in PCa cell lines PC-3 and DU145. Moreover, we observed that the expressions of P21 were increased while the levels of cycinD1 and bcl-2 were decreased after knockdown of REGγ in PCa cells. And the stabilization of P21 was enhanced after REGγ knockdown in PC-3 cells. In summary, our findings suggest that REGγ may play important roles in prostate cancer and may serve as a novel therapeutic target in the treatment of PCa patients.
Indexed as
Identifiers
28861169PMC5575192W2987091734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.